학술논문
COVID-19 in HSCT recipients: a collaborative study of the Brazilian Society of Marrow Transplantation (SBTMO)
Document Type
Original Paper
Author
Daudt, Liane Esteves; Corso, Mariana Cristina Moraes; Kerbauy, Mariana Nassif; de Assis, Luiz Henrique dos Santos; Rechenmacher, Ciliana; Colturato, Iago; Barbieri, Fernanda Rodrigues; Rocha, Vanderson; Mariano, Livia; Garcia, Julia Lopes; Dantas, Vanessa Esther Cavalcanti Barreto; Loth, Gisele; Funke, Vaneuza Araujo Moreira; Pelegrina, Polliany Roberta Dorini; Duarte, Fernando Barroso; da Silva, Roberto Luiz; Araújo, Marco Aurelio Salvino; Carlesse, Fabianne Altruda de Moraes Costa; de Sousa, Ana Virginia Lopes; Maia, Luana Azevedo; Fernandes, Juliana Folloni; Rodrigues, Celso Arrais; Bonfim, Carmem; Martins, Leticia Navarro Gordan Ferreira; Cipolotti, Rosana; Xavier, Erick Menezes; Gomes, Alessandra Araújo; Morales, Hugo Manuel Paz; Simioni, Anderson J.; Soares, Victor Jablonski; Michalowski, Mariana Bohns; Hamerschlak, Nelson; Machado, Clarisse Martins
Source
Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation. 57(3):453-459
Subject
Language
English
ISSN
0268-3369
1476-5365
1476-5365
Abstract
In the COVID-19 scenario, patients undergoing hematopoietic stem cell transplantation (HSCT) infected with SARS-CoV-2 may have an increased risk of death. Through a national multicenter study, we aimed to describe the impact of COVID-19 on the survival of HSCT recipients in Brazil. Eighty-six patients with a confirmed diagnosis of SARS-CoV-2 (92% by RT-PCR) were included. There were 24 children and 62 adults receiving an autologous (n = 25) and allogeneic (n = 61) HSCT for malignant (n = 72) and non-malignant (n = 14) disorders. Twenty-six patients died, (10 on autologous (38%) and 16 patients (62%) on allogeneic group). The estimated overall survival (OS) at day 40 was 69%. Adults had decreased OS compared to children (66% vs 79%, p = 0.03). The severity of symptoms at the time of diagnosis, ECOG score, laboratory tests (C-reactive protein, urea values) were higher in patients who died (p < 0.05). In conclusion, HSCT recipients infected with SARS-CoV-2 have a high mortality rate mainly in adults and patients with critical initial COVID-19 presentation. These findings show the fragility of HSCT recipients with SARS-CoV-2 infection. Therefore, the importance of adherence to preventive measures is evident, in addition to prioritizing the vaccination of family members and the HSCT team.